NextGen News
NextGen Pharma is proud to welcome our newest client:
Randox Laboratories Ltd., of Northern Ireland, is a global leader in diagnostics and biomarker solutions with 60,000 end users in 130 countries. Due to its unrivalled package of sensitivity, precision and reproducibility, Randox’s Biochip Array Technology, a single platform enabling both protein and nucleic acid multiplex analysis, is considered the multiplex platform of choice. The fully automated ‘Evidence’ Biochip analyzer is an FDA 510K approved system, with FDA and CE marked immunoassay arrays available; all developed in-house at Randox’s FDA inspected, ISO 13485 accredited manufacturing facilities. Randox has over 4,500 labs using their instrumentation and strong regulatory expertise with over 400 FDA approved and 850 CE marked tests, ensuring Randox is ideally placed to support drug development with cutting edge diagnostic and biomarker solutions.
Complete Range of Outsourcing Options
NextGen Pharma Technologies, Inc. provides sales representation for innovative and niche CROs to Pharmaceutical and Biotechnology R&D decision makers. NextGen offers a complete range of outsourcing options - from discovery support through IND/NDA support and beyond. NextGen represents companies with new innovative technologies that improve lead optimization and drug candidate selection using: Predictive ADME; in vivo efficacy; safety pharmacology, xenografts; behavioral pharmacology; unique animal and surgical models; BBB; mouse with a human liver; Indications Discovery Screening, drug development support such a GLP, Toxicology, ADME - rodents to NHP’s; formulation development; clinical supply manufacturing; GLP bioanalytical support; GLP protein and peptide analysis. These technologies can reduce development time and cost. In these uncertain economic times, NG clients offer a lower cost/higher value alternative to large multi-disciplined CROs.
For an overview of NextGen companies click here.
